StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)

Close on Nov 17, 2026Market cap $50.42MP/E –Yield –

Tonix Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Tonix Pharmaceuticals's cash was $176.23M at Jun 30, 2026. For fiscal 2025 it was $207.64M, up 108.3% from the year before. Over ten years it grew 19.6% a year on average. The highest annual figure on record is $207.64M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$207.64M+108.3%
FY2024Dec 31, 2024$99.68M+285.6%
FY2023Dec 31, 2023$25.85M-78.5%
FY2022Dec 31, 2022$120.47M-32.7%
FY2021Dec 31, 2021$178.90M+131.4%
FY2020Dec 31, 2020$77.31M+581.2%
FY2019Dec 31, 2019$11.35M-54.8%
FY2018Dec 31, 2018$25.13M-1.8%
FY2017Dec 31, 2017$25.59M+34.4%
FY2016Dec 31, 2016$19.03M-45.1%
FY2015Dec 31, 2015$34.69M-9.1%
FY2014Dec 31, 2014$38.18M+365.5%
FY2013Dec 31, 2013$8.20M+359.5%
FY2012Dec 31, 2012$1.79M+4253.7%
FY2011Dec 31, 2011$41.00K-37.3%
FY2010Dec 31, 2010$65.36K+6037.0%
FY2009Dec 31, 2009$1.07K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$176.23M+39.6%
Q1 FY2026Mar 31, 2026$185.47M+40.8%
Q4 FY2025Dec 31, 2025$207.64M+108.3%
Q3 FY2025Sep 30, 2025$190.06M+573.2%
Q2 FY2025Jun 30, 2025$126.24M+2937.4%
Q1 FY2025Mar 31, 2025$131.72M+1768.6%
Q4 FY2024Dec 31, 2024$99.68M+285.6%
Q3 FY2024Sep 30, 2024$28.23M+308.3%
Q2 FY2024Jun 30, 2024$4.16M-83.8%
Q1 FY2024Mar 31, 2024$7.05M-90.2%
Q4 FY2023Dec 31, 2023$25.85M-78.5%
Q3 FY2023Sep 30, 2023$6.91M-95.1%
Q2 FY2023Jun 30, 2023$25.62M-82.4%
Q1 FY2023Mar 31, 2023$71.98M-48.7%
Q4 FY2022Dec 31, 2022$120.47M-32.7%
Q3 FY2022Sep 30, 2022$139.98M-23.5%
Q2 FY2022Jun 30, 2022$145.48M-12.2%
Q1 FY2022Mar 31, 2022$140.44M-14.5%
Q4 FY2021Dec 31, 2021$178.90M+131.4%
Q3 FY2021Sep 30, 2021$182.97M+227.3%
Q2 FY2021Jun 30, 2021$165.72M+200.6%
Q1 FY2021Mar 31, 2021$164.21M+433.8%
Q4 FY2020Dec 31, 2020$77.31M+581.2%
Q3 FY2020Sep 30, 2020$55.90M+452.1%
Q2 FY2020Jun 30, 2020$55.12M+350.0%
Q1 FY2020Mar 31, 2020$30.77M+85.9%
Q4 FY2019Dec 31, 2019$11.35M-54.8%
Q3 FY2019Sep 30, 2019$10.12M-31.5%
Q2 FY2019Jun 30, 2019$12.25M-26.9%
Q1 FY2019Mar 31, 2019$16.55M-14.4%
Q4 FY2018Dec 31, 2018$25.13M-1.8%
Q3 FY2018Sep 30, 2018$14.77M-49.7%
Q2 FY2018Jun 30, 2018$16.77M-51.3%
Q1 FY2018Mar 31, 2018$19.34M-3.4%
Q4 FY2017Dec 31, 2017$25.59M+34.4%
Q3 FY2017Sep 30, 2017$29.40M+87.9%
Q2 FY2017Jun 30, 2017$34.44M–
Q1 FY2017Mar 31, 2017$20.03M–
Q4 FY2016Dec 31, 2016$19.03M–
Q3 FY2016Sep 30, 2016$15.64M–

More Tonix Pharmaceuticals figures

See a number that looks wrong?